NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ZLAB

Zai Lab Limited ADR

Jun 30 • 04:00PM ET

34.97

Dollar change +0.23
Percentage change 0.66	%

Healthcare • Biotechnology • China • NASD

Peers: AMGN GILD BMY MRNA VRTX REGN INCY BIIB SAGE NBIX

| Held by: IBB SBIO CANC PGJ CGNG FMED ONEQ FFTY PIEQ BBP

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.50	Insider Own	1.31%	Shs Outstand	110.59M	Perf Week	-2.89%
Market Cap	3.87B	Forward P/E	79.50	EPS next Y	0.44	Insider Trans	-24.52%	Shs Float	109.14M	Perf Month	11.69%
Enterprise Value	3.20B	PEG	-	EPS next Q	-0.41	Inst Own	50.52%	Short Float	4.02%	Perf Quarter	-6.22%
Income	-252.07M	P/S	9.24	EPS this Y	48.74%	Inst Trans	-4.97%	Short Ratio	3.60	Perf Half Y	30.05%
Sales	418.33M	P/B	4.68	EPS next Y	133.00%	ROA	-23.32%	Short Interest	4.39M	Perf YTD	33.52%
Book/sh	7.48	P/C	4.51	EPS next 5Y	-	ROE	-32.05%	52W High	44.34 -21.13%	Perf Year	94.60%
Cash/sh	7.75	P/FCF	-	EPS past 3/5Y	30.00% -3.18%	ROIC	-30.63%	52W Low	16.01 118.43%	Perf 3Y	5.49%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	40.35% 98.38%	Gross Margin	63.45%	Volatility	3.47% 3.94%	Perf 5Y	-55.38%
Dividend TTM	-	EV/Sales	7.66	EPS Y/Y TTM	28.63%	Oper. Margin	-64.09%	ATR (14)	1.87	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.09	Sales Y/Y TTM	43.72%	Profit Margin	-60.26%	RSI (14)	47.87	Recom	1.38
Dividend Gr. 3/5Y	- -	Current Ratio	3.26	EPS Q/Q	18.43%	SMA20	-5.76%	Beta	0.98	Target Price	52.41
Payout	-	Debt/Eq	0.24	Sales Q/Q	22.19%	SMA50	4.79%	Rel Volume	0.70	Prev Close	34.74
Employees	1869	LT Debt/Eq	0.02	Earnings	May 08 BMO	SMA200	17.31%	Avg Volume	1.22M	Price	34.97
IPO	Sep 20, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	92.78% -5.41%	Trades		Volume	847,272	Change	0.66%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$55
Mar-03-25	Downgrade	BofA Securities	Buy → Neutral	$29 → $36.10
Dec-14-23	Initiated	Morgan Stanley	Overweight	$47.50
Aug-10-23	Initiated	Cantor Fitzgerald	Overweight	$70
Jan-21-22	Initiated	Macquarie	Outperform	$64
Oct-12-21	Initiated	Bernstein	Mkt Perform
Apr-28-20	Initiated	Goldman	Buy
Apr-15-20	Initiated	Guggenheim	Buy	$75
Jul-12-19	Initiated	BofA/Merrill	Buy
Jul-05-19	Initiated	Macquarie	Outperform
Jan-29-19	Initiated	Credit Suisse	Outperform
Nov-21-18	Initiated	Jefferies	Buy
Jun-21-18	Resumed	Leerink Partners	Outperform	$43
Feb-14-18	Upgrade	JP Morgan	Neutral → Overweight
Oct-16-17	Initiated	Leerink Partners	Outperform	$42
Oct-16-17	Initiated	JP Morgan	Neutral	$32

Show Previous Ratings

Jun-30-25 09:05AM	Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer (Business Wire)
Jun-13-25 07:00AM	Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 (Business Wire)
Jun-02-25 07:00AM	Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting (Business Wire)
May-31-25 03:08PM	Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
May-30-25 07:30AM	Zai Lab Announces Participation in Investor Conferences in June 2025 (Business Wire)
06:08AM	Loading…
May-20-25 06:08AM	FDA grants fast track status to Zai Lab's lung cancer treatment (Pharmaceutical Business Review)
May-19-25 07:00AM	Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer (Business Wire) +6.66%
May-09-25 03:11AM	Zai Lab Ltd (ZLAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
May-08-25 10:00AM	Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
06:00AM	Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates (Business Wire)
May-07-25 11:17AM	Zai Lab Q1 2025 Earnings Preview (Seeking Alpha)
May-05-25 05:58PM	Zai Lab Limited (ZLAB): Among the Best Breakout Stocks to Buy According to Analysts (Insider Monkey) -5.07%
Apr-28-25 08:09AM	Baron Emerging Markets Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-25-25 01:12PM	Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025 (Business Wire) -5.33%
Apr-23-25 10:56AM	Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting (Business Wire)
07:30AM	Loading…
Apr-21-25 07:30AM	Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors (Business Wire)
Apr-17-25 05:00AM	Bulls In A China Shop: 5 Chinese Stocks To Ride Out The Trade War (Seeking Alpha)
Apr-15-25 12:00PM	All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy (Zacks)
Apr-14-25 09:10AM	Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last? (Zacks) +6.70%
07:30AM	Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025 (Business Wire)
Apr-10-25 01:39PM	Zai Lab Limited (ZLAB): Among Stocks Insiders Sold in April After Trump's Tariff Rollout (Insider Monkey) -10.13%
Mar-26-25 07:00AM	Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting (Business Wire)
Mar-21-25 05:16PM	Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth (SeekingAlpha) -6.00%
Mar-20-25 01:05PM	Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks (SeekingAlpha)
Mar-14-25 10:40AM	Is Zai Lab Limited (ZLAB) the Best Performing Growth Stock in 2025? (Insider Monkey) +5.70%
Mar-13-25 08:35PM	Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer (TipRanks)
Mar-12-25 07:30PM	Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer (Business Wire)
Mar-04-25 09:55AM	Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet (Zacks) +7.15%
Mar-03-25 07:30AM	Zai Lab Announces Participation in Investor Conferences in March 2025 (Business Wire) -8.40%
Feb-28-25 02:09AM	Zai Lab Ltd (ZLAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Path to Profitability (GuruFocus.com)
12:43PM	Loading…
Feb-27-25 12:43PM	China Biotech's Sales Jump 66% But Bottom Line Misses Views (Investor's Business Daily)
06:00AM	Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates (Business Wire)
Feb-26-25 11:59AM	Is Zai Lab Limited (ZLAB) the Best Performing Mid Cap Stock to Buy According to Analysts? (Insider Monkey)
Feb-24-25 10:25AM	Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains? (Zacks)
Jan-28-25 09:55AM	Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to Trade (Zacks)
07:30AM	Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025 (Business Wire)
Jan-23-25 10:14AM	FDA grants ODD status to Zai Labs lung cancer treatment (Pharmaceutical Technology)
01:41AM	Why Is Andreas Halvorsen Bullish On Zai Lab Limited (ZLAB) Now? (Insider Monkey)
Jan-22-25 11:15PM	Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC) (Business Wire)
Jan-20-25 07:06PM	Heres Why Analysts Are Bullish on Zai Lab Limited (ZLAB) (Insider Monkey)
Jan-17-25 07:30AM	Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia (Business Wire)
Jan-15-25 03:58PM	Zai Labs announces positive results in China arm of Phase III cervical cancer trial (Clinical Trials Arena)
07:30AM	Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer (Business Wire)
Jan-11-25 07:41AM	Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement (TipRanks)
Jan-10-25 07:30AM	Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (Business Wire)
07:30AM	Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore (Business Wire)
Jan-09-25 06:30PM	Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate (Business Wire)
Dec-24-24 12:00PM	Zai Lab Limited (ZLAB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Dec-12-24 07:30AM	Zai Lab Announces Participation in Investor Conference in January 2025 (Business Wire)
Dec-03-24 07:17AM	Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint (TipRanks)
Dec-02-24 10:12AM	NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients (Benzinga)
07:02AM	Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
Nov-27-24 11:05PM	Zai Lab Announces the Inclusion of AUGTYRO (repotrectinib) for ROS1+ NSCLC and Other Updates in Chinas National Reimbursement Drug List (Business Wire)
Nov-22-24 06:36AM	Zai Lab and Pfizer to commercialise XACDURO in China (Pharmaceutical Technology)
Nov-21-24 04:00AM	Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO (Sulbactam-Durlobactam) (Business Wire)
Nov-18-24 09:15AM	Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares (Business Wire) -6.98%
Nov-14-24 07:43PM	Zai Lab Announces Pricing of Public Offering of American Depositary Shares (Business Wire) -10.95%
Nov-13-24 04:12PM	Zai Lab Announces Proposed Public Offering of American Depositary Shares (Business Wire)
02:05AM	Zai Lab Ltd (ZLAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Path to Profitability (GuruFocus.com)
Nov-12-24 12:00PM	Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics (Zacks) -6.85%
07:03AM	Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo (Pharmaceutical Technology)
06:30AM	Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates (Business Wire)
Nov-11-24 07:30AM	Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China (Business Wire)
07:30AM	argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China (GlobeNewswire)
Oct-30-24 06:34AM	Zai Lab presents positive outcomes from KarXT Phase III trial for schizophrenia (Clinical Trials Arena)
Oct-29-24 07:30AM	Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China (Business Wire)
Oct-25-24 05:36AM	Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last? (Zacks)
Oct-24-24 04:05PM	Zai Lab, A Top 6% Stock, Launched To A 16-Month High On Its 'Impressive' Results (Investor's Business Daily) +14.65%
05:15AM	ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer (Business Wire)
Oct-18-24 07:30AM	Zai Lab Announces Participation in November and December Investor Conferences (Business Wire)
Oct-17-24 08:00AM	Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 (Business Wire)
Oct-16-24 07:30AM	Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024 (Business Wire) +5.57%
Oct-09-24 07:00AM	Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024 (Business Wire)
Sep-27-24 05:17AM	Zai Lab Limited (ZLAB) Surges 11.1%: Is This an Indication of Further Gains? (Zacks)
Sep-17-24 01:32PM	Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024 (Business Wire)
Aug-29-24 04:09PM	Zai Lab Limited (ZLAB): Top ADR Stock According to Hedge Funds (Insider Monkey)
Aug-27-24 08:30AM	Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024 (Business Wire)
Aug-22-24 07:30AM	Zai Lab Announces Participation in September Investor Conferences (Business Wire)
Aug-06-24 04:05PM	Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates (Business Wire) -8.06%
Jul-26-24 08:04AM	Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem (InvestorPlace)
Jul-17-24 06:32AM	China NMPA approves Zai Lab-argenxs efgartigimod alfa for gMG (Pharmaceutical Technology)
Jul-16-24 12:30AM	argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China (GlobeNewswire)
12:15AM	Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China (Business Wire)
Jul-15-24 02:53PM	Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy (Business Wire)
Jul-10-24 07:30AM	Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024 (Business Wire)
Jun-27-24 07:00PM	Insider Selling: Chairperson & CEO Ying Du Sells Shares of Zai Lab Ltd (ZLAB) (GuruFocus.com)
Jun-11-24 04:05PM	Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D (Business Wire)
Jun-04-24 11:59AM	Qiming's Nisa Leung Made the 2024 Forbes Midas List (PR Newswire) +7.17%
May-27-24 09:09AM	Here's Why Zai Lab Limited (ZLAB) Fell in Q1 (Insider Monkey)
May-23-24 08:52AM	Zai Lab doses first subject in Phase II plaque psoriasis treatment trial (Clinical Trials Arena) -5.46%
May-22-24 07:30AM	Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis (Business Wire)
May-20-24 06:31AM	Chinas NMPA approves Zai Labs XACDURO NDA for pneumonia (Pharmaceutical Technology) +7.42%
04:06AM	Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment (MT Newswires)
12:21AM	Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China (Business Wire)
May-17-24 02:36AM	Insider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells Shares (GuruFocus.com)
May-16-24 07:30AM	Zai Lab Announces Participation in May and June Investor Conferences (Business Wire)
May-14-24 08:41AM	Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator (MT Newswires)
07:30AM	Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China (Business Wire)
May-13-24 11:42AM	BMS and Zai Labs Augtyro gains NMPA approval to treat NSCLC (Pharmaceutical Technology) +7.17%
08:51AM	Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro (MT Newswires)

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Du Ying	Officer	Jun 30 '25	Proposed Sale	35.52	6,918	245,724		Jun 30 03:10 PM
Edmondson Frazor Titus III	Chief Legal Officer	Jun 26 '25	Sale	36.13	5,877	212,348	39,098	Jun 27 04:15 PM
Du Ying	Chairperson & CEO	Jun 26 '25	Sale	36.13	23,669	855,208	514,982	Jun 27 04:15 PM
Chen Yajing	Chief Financial Officer	Jun 26 '25	Sale	36.13	2,675	96,653	21,004	Jun 27 04:15 PM
Edmondson Frazor Titus III	Officer	Jun 26 '25	Proposed Sale	36.13	5,877	212,345		Jun 26 04:41 PM
Chen Yajing	Officer	Jun 26 '25	Proposed Sale	36.13	2,675	96,652		Jun 26 04:29 PM
Du Ying	Officer	Jun 26 '25	Proposed Sale	36.13	23,669	855,196		Jun 26 04:15 PM
Lis William	Director	Jun 20 '25	Sale	35.67	13,814	492,745	35,106	Jun 23 04:10 PM
Lis William	Director	Jun 20 '25	Proposed Sale	35.67	13,814	492,745		Jun 20 09:44 AM
Chen Yajing	Chief Financial Officer	Jun 02 '25	Sale	30.00	9,618	288,540	17,429	Jun 04 04:34 PM
Chen Yajing	Officer	Jun 02 '25	Proposed Sale	30.00	9,618	288,540		Jun 02 02:23 PM
Du Ying	Chairperson & CEO	May 13 '25	Option Exercise	0.60	50,000	30,000	529,851	May 15 04:27 PM
Du Ying	Chairperson & CEO	May 14 '25	Option Exercise	0.60	46,389	27,833	526,240	May 15 04:27 PM
Du Ying	Chairperson & CEO	May 13 '25	Sale	28.57	50,000	1,428,650	479,851	May 15 04:27 PM
Du Ying	Chairperson & CEO	May 14 '25	Sale	28.09	46,389	1,302,857	479,851	May 15 04:27 PM
Du Ying	Officer	May 14 '25	Proposed Sale	28.90	46,389	1,340,642		May 14 09:43 AM
Morrison Scott W	Director	May 09 '25	Sale	30.05	23,799	715,086	23,702	May 13 04:48 PM
Du Ying	Chairperson & CEO	May 09 '25	Option Exercise	0.60	50,000	30,000	529,851	May 13 04:48 PM
Du Ying	Chairperson & CEO	May 12 '25	Option Exercise	0.60	50,000	30,000	529,851	May 13 04:48 PM
Du Ying	Chairperson & CEO	May 09 '25	Sale	29.62	50,000	1,481,140	479,851	May 13 04:48 PM
Du Ying	Chairperson & CEO	May 12 '25	Sale	29.44	50,000	1,472,167	479,851	May 13 04:48 PM
Du Ying	Officer	May 13 '25	Proposed Sale	29.09	50,000	1,454,500		May 13 01:09 PM
Du Ying	Officer	May 12 '25	Proposed Sale	29.18	50,000	1,459,000		May 12 02:53 PM
Du Ying	Officer	May 09 '25	Proposed Sale	29.62	50,000	1,481,141		May 09 04:13 PM
Morrison Scott W	Director	May 09 '25	Proposed Sale	30.05	23,799	715,086		May 09 11:35 AM
Smiley Joshua L	See Remarks	Apr 04 '25	Sale	33.11	3,354	111,044	67,345	Apr 07 04:48 PM
Edmondson Frazor Titus III	Chief Legal Officer	Apr 04 '25	Sale	33.11	1,874	62,044	30,375	Apr 07 04:48 PM
Du Ying	Chairperson & CEO	Apr 04 '25	Sale	33.11	2,945	97,503	479,851	Apr 07 04:48 PM
Chen Yajing	Chief Financial Officer	Apr 04 '25	Sale	33.11	924	30,592	27,047	Apr 07 04:48 PM
Amado Rafael	See Remarks	Apr 04 '25	Sale	33.11	3,029	100,284	45,178	Apr 07 04:48 PM
Edmondson Frazor Titus III	Officer	Apr 04 '25	Proposed Sale	33.11	1,874	62,045		Apr 04 03:22 PM
Smiley Joshua L	Officer	Apr 04 '25	Proposed Sale	33.11	3,354	111,046		Apr 04 03:19 PM
Amado Rafael	Officer	Apr 04 '25	Proposed Sale	33.11	3,029	100,286		Apr 04 03:15 PM
Du Ying	Officer	Apr 04 '25	Proposed Sale	33.11	2,945	97,505		Apr 04 03:15 PM
Chen Yajing	Officer	Apr 04 '25	Proposed Sale	33.11	924	30,592		Apr 04 03:13 PM
Edmondson Frazor Titus III	Chief Legal Officer	Apr 02 '25	Sale	35.89	4,369	156,821	27,217	Apr 03 05:07 PM
Du Ying	Chairperson & CEO	Apr 02 '25	Sale	35.89	5,808	208,472	476,046	Apr 03 05:07 PM
Chen Yajing	Chief Financial Officer	Apr 02 '25	Sale	35.89	5,280	189,520	25,471	Apr 03 05:06 PM
Amado Rafael	See Remarks	Apr 02 '25	Sale	35.89	7,541	270,677	42,816	Apr 03 05:06 PM
Smiley Joshua L	See Remarks	Apr 02 '25	Sale	35.89	11,740	421,396	63,554	Apr 03 05:06 PM
Amado Rafael	Officer	Apr 02 '25	Proposed Sale	35.89	7,541	270,678		Apr 02 05:14 PM
Smiley Joshua L	Officer	Apr 02 '25	Proposed Sale	35.89	11,740	421,398		Apr 02 05:11 PM
Du Ying	Officer	Apr 02 '25	Proposed Sale	35.89	5,808	208,474		Apr 02 05:10 PM
Chen Yajing	Officer	Apr 02 '25	Proposed Sale	35.89	5,280	189,521		Apr 02 05:04 PM
Edmondson Frazor Titus III	Officer	Apr 02 '25	Proposed Sale	35.89	4,369	156,822		Apr 02 05:00 PM
Amado Rafael	See Remarks	Mar 17 '25	Sale	38.41	3,000	115,230	30,834	Mar 19 04:41 PM
Amado Rafael	Officer	Mar 17 '25	Proposed Sale	38.41	3,000	115,230		Mar 17 09:48 AM
Du Ying	Officer	Mar 05 '25	Proposed Sale	35.55	46,389	1,649,122		Mar 05 04:11 PM
GAYNOR RICHARD	Director	Mar 05 '25	Proposed Sale	35.07	2,500	87,675		Mar 05 11:22 AM
Edmondson Frazor Titus III	Chief Legal Officer	Feb 28 '25	Sale	32.98	14,544	479,661	14,328	Mar 04 05:11 PM
Lis William	Director	Feb 28 '25	Sale	32.98	15,000	494,700	38,089	Mar 04 05:11 PM
Du Ying	Chairperson & CEO	Feb 28 '25	Option Exercise	0.60	50,000	30,000	544,117	Mar 04 05:11 PM
Du Ying	Chairperson & CEO	Mar 03 '25	Option Exercise	0.60	50,000	30,000	544,117	Mar 04 05:11 PM
Du Ying	Chairperson & CEO	Feb 28 '25	Sale	34.47	50,000	1,723,466	494,117	Mar 04 05:11 PM
Du Ying	Chairperson & CEO	Mar 03 '25	Sale	32.44	50,000	1,622,141	494,117	Mar 04 05:11 PM
Du Ying	Officer	Mar 04 '25	Proposed Sale	32.27	50,000	1,613,500		Mar 04 11:27 AM
Du Ying	Officer	Mar 03 '25	Proposed Sale	33.70	50,000	1,685,000		Mar 03 11:49 AM
Du Ying	Officer	Feb 28 '25	Proposed Sale	32.98	50,000	1,649,000		Feb 28 01:24 PM
Lis William	Director	Feb 28 '25	Proposed Sale	32.98	15,000	494,700		Feb 28 01:22 PM
Edmondson Frazor Titus III	Officer	Feb 28 '25	Proposed Sale	32.98	14,544	479,661		Feb 28 10:52 AM
Amado Rafael	See Remarks	Dec 31 '24	Sale	26.28	7,583	199,289	33,834	Jan 02 04:13 PM
Amado Rafael	Officer	Dec 31 '24	Proposed Sale	26.28	7,583	199,287		Dec 31 03:09 PM
Chen Yajing	Chief Financial Officer	Nov 04 '24	Sale	30.66	167	5,121	15,494	Nov 05 04:31 PM
Chen Yajing	Officer	Nov 04 '24	Proposed Sale	30.66	167	5,121		Nov 04 03:37 PM
Chen Yajing	Chief Financial Officer	Oct 02 '24	Sale	25.40	301	7,645	15,161	Oct 03 04:14 PM
Chen Yajing	Officer	Oct 02 '24	Proposed Sale	25.40	301	7,645		Oct 02 03:06 PM
Reinhart Harald	Former Officer	Sep 26 '24	Proposed Sale	22.00	60,000	1,320,000		Sep 26 03:52 PM
Reinhart Harald	Former Officer	Sep 19 '24	Proposed Sale	21.16	70,000	1,481,095		Sep 19 04:55 PM
GAYNOR RICHARD	Director	Sep 03 '24	Sale	19.50	2,500	48,750	46,568	Sep 05 04:13 PM
GAYNOR RICHARD	Director	Sep 03 '24	Proposed Sale	19.50	2,500	48,750		Sep 03 12:12 PM
Edmondson Frazor Titus III	Chief Legal Officer	Aug 19 '24	Sale	16.95	1,924	32,619	28,872	Aug 20 04:42 PM
Smiley Joshua L	See Remarks	Aug 16 '24	Sale	16.67	4,352	72,561	43,232	Aug 19 04:45 PM
Edmondson Frazor Titus III	Officer	Aug 19 '24	Proposed Sale	16.95	1,924	32,620		Aug 19 03:16 PM
Chen Yajing	Chief Financial Officer	Aug 15 '24	Sale	16.06	422	6,779	14,542	Aug 16 04:38 PM
Smiley Joshua L	Officer	Aug 16 '24	Proposed Sale	16.67	4,352	72,560		Aug 16 03:14 PM
Chen Yajing	Officer	Aug 15 '24	Proposed Sale	16.06	422	6,779		Aug 15 03:37 PM
Amado Rafael	See Remarks	Aug 12 '24	Sale	16.20	3,115	50,463	20,417	Aug 14 04:18 PM
Amado Rafael	Officer	Aug 12 '24	Proposed Sale	16.20	3,115	50,463		Aug 12 11:30 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZLAB

Zai Lab Limited ADR

Upgrade your FINVIZ experience